Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Nanobiotix ( (NBTX) ) is now available.
On May 28, 2025, Nanobiotix announced its participation in the Jefferies Global Healthcare Investor Conference, scheduled for June 5, 2025, in New York. The company’s Chief Financial & Business Officer, Bart van Rhijn, will represent Nanobiotix in fireside chats, which will be webcast live. This participation underscores Nanobiotix’s active engagement with the investment community and highlights its ongoing efforts to expand its market presence and communicate its innovative approaches in the biotechnology sector.
The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The overall stock score of 43 reflects Nanobiotix’s substantial financial challenges, including declining revenues, negative profitability, and a high leverage ratio. While the strategic partnership with JNJ offers potential future milestones and an extended cash runway, current financial performance and valuation metrics remain under significant pressure. Technical indicators show some positive momentum, but overall stock performance is hindered by underlying financial instability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company that specializes in nanoparticle-based therapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases. Founded in 2003 and headquartered in Paris, France, the company is listed on both Euronext Paris and the Nasdaq Global Select Market. It holds over 25 umbrella patents across three nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders.
Average Trading Volume: 12,032
Technical Sentiment Signal: Sell
Current Market Cap: $184M
Learn more about NBTX stock on TipRanks’ Stock Analysis page.